Chikungunya Club Meeting (7.24.2026)
Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com.
Read Article
RheumIQ: True or False: Severe allergic reactions to allopurinol are more common in patients with chronic kidney disease than in the general population.
See if you got it right at https://t.co/LATb1P18Sh. https://t.co/dFdrhso1oU
Dr. John Cush @RheumNow( View Tweet )
The Lancet Rheumatology has a good editorial about the avacopan bad news reports with EMA, FDA and Japan issuing negative opinions that threaten the drugs future. Yet, since approval real world data on avacopan has been favorable w/ less steroid toxicity & most hepatotoxicity https://t.co/k6ebVeWv2K
Dr. John Cush @RheumNow( View Tweet )
Allopurinol - severe allergic reactions are estimated at 0.4%-2%, rising to 8–18% in patients with chronic kidney disease. Being HLA-B*58:01 (+) dramatically increases risk (OR 117).
For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/fTuc4lYvJz
Dr. John Cush @RheumNow( View Tweet )
Genetic study of 16 pts w/ Allopurinol-induced severe cutaneous adverse Rxn (SJS/TEN) shows 2 class I alleles to be associated: HLA-B*58:01 (OR, 28.0 [95% CI, 8.6-100.6]) and HLA-A*34:02 (OR, 20.6 [95% CI, 3.3-131.1]). Both explain 80% risk in US pts https://t.co/OxDXuWCbup https://t.co/oky61JImQV
Dr. John Cush @RheumNow( View Tweet )
Psoriatic Arthritis: EULAR 2026 Recap
https://t.co/tBMu4CEn0o https://t.co/iztShOHxOf
Dr. John Cush @RheumNow( View Tweet )
From 2015-2024, 148 inflam arthritis pts (43 SpA, 35 PsA, 50 RA) w/ a prior cancer were followed 58.1 mos. 24 (19%) had CA recurrence/progression. Post-CA exposure to b/ts-DMARDs did not incr. recurrence risk after adjusting for age & comorbidity burden. https://t.co/MHKIqwyjNN https://t.co/uhOdq1cCPW
Dr. John Cush @RheumNow( View Tweet )
RHEUM SURVEY Q: Which gout drug has the greatest toxicity risk? Answer here>> https://t.co/EQrEjD9237
Dr. John Cush @RheumNow( View Tweet )
Expert Perspective on Calcium Pyrophosphate Deposition Disease
A recent perspective by Tedeschi tackles many unresolved issues around CPPD diagnosis, classification, and management, including the lack of clinical trials or FDA approved treatments.
Read Article
Pragmatism in Gout: How therapeutic choices can have multiple benefits
William James famously wrote in Pragmatism, “There can be no difference anywhere that doesn’t make a difference elsewhere.” Gout treatment offers a striking medical example of that idea. Drugs prescribed to calm flares or lower uric acid are designed with one primary goal in
Read Article
Low dose ASA (81mg or 325mg) increase gout attacks by 81% (RR 1.81). Effect nullified by allopurinol use.
For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/sSm4s3vUtE
Dr. John Cush @RheumNow( View Tweet )
ACP Position Paper on Dietary Supplements
More than half of U.S. adults use dietary supplements, yet only a quarter use supplements recommended by a healthcare professional, and current law allows supplements to reach the market without a premarket safety evaluation, unlike https://t.co/gwLG4ElfCq
Dr. John Cush @RheumNow( View Tweet )
Fibromyalgia: Diagnosis and Management
Fibromyalgia (FM) affects 4–6% of the U.S. population, with nearly a 2 fold female predominance. Nociplastic pain underlies the pathophysiology of FM. CNS hypersensitization to both painful and non-painful stimuli occurs with little or no tissue pathology. Framing FM as a disorder of CNS
Read Article
Psoriatic Arthritis: EULAR 2026 Recap
Years of IL-17 vs. IL-23 debate in PsA finally got tested head-to-head: bimekizumab outperformed risankizumab on joint outcomes in the BE BOLD trial, while a GLP-1 combination study suggests weight and metabolic status are active drivers of PsA — not just comorbidities. This recap also digs into
Read Article
Seronegative RA Disease Activity (7.17.2026)
Dr. Jack Cush reviews the news, journal articles and Gout features from this past week on RheumNow.com.
Read Article
ACP Position Paper on Dietary Supplements
More than half of U.S. adults use dietary supplements, yet only a quarter use supplements recommended by a healthcare professional, and current law lets supplements reach the market with no premarket safety evaluation, unlike drugs or food additives. The paper notes that under DSHEA, dietary
Read Article
Guidelines to Spot Cancer in High Risk Dermatomyositis
MedPage Today
International guidelines can help identify dermatomyositis patients with a particularly high risk for cancer, according to a retrospective single-center U.S. study.
Read Article
FDA - a 120Year History Protecting Americans. Nice overview.
- Began 1906 (as Bureau of Chemistry) w/ Pure Food & Drugs Act
- 1930 changed to Food and Drug Administration
- 1938 Food, Drug, and Cosmetics Act
- 1960s denied thalidomide approval https://t.co/3Ey98M9sxw My https://t.co/JS36EfJ19k
Dr. John Cush @RheumNow( View Tweet )
True or False: There is an available antidote for colchicine overdose. Check your answer in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/RgJ4xEAuZA
Dr. John Cush @RheumNow( View Tweet )
FDA Delays Gout Drug NASP with Complete Response Letter
On June 26, 2026, SOBI received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) that will delay a decision on NASP, pending the company's answer to questions regarding the drugs https://t.co/NmPbWmYd0p
Dr. John Cush @RheumNow( View Tweet )
Netherlands pragmatic open-label RCT from 8 rheum centres tested T2T vs Sx Rx in 308 Gout pts starting ULT (87% male; 66 yrs). Remission (no flares & pain < 2) betw 18-24 mos was more in T2T pts (39% vs 24%; p=0.02), but more AE w/ Sx driven Rx (53 vs 42%) https://t.co/5g2dY5y900
Dr. John Cush @RheumNow( View Tweet )
Gout Cavalcade (7.10.2026)
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.
Read Article
Do we need Better Strategies to Prevent Osteoporotic Fractures?
In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.
Read Article
NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan
The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. https://t.co/GOVyk5poNq
Dr. John Cush @RheumNow( View Tweet )
FDA Delays Gout Drug NASP with Complete Response Letter
At the end of June, Sobi was awaiting an FDA decision on its Biologics License Application (BLA) for NASP (nanoencapsulated sirolimus plus pegadricase) for the treatment of adult patients with uncontrolled gout. On June 26, 2026, SOBI received a Complete Response Letter from the U.S. FDA that
Read ArticleTherapeutic Updates
Lupus Nephritis
Sponsored by RheumNow
View our six video perspectives on lupus nephritis, including Management of CKD in Lupus Nephritis.
Read Post
Recent Blogs
Dr. Jack Cush reviews Gout in this continuing series for Advanced Practice Rheum. Review the companion slide deck here.
Podcasts
ACR 2025 Daily Podcasts Day2d
EULAR 2021 - Day2b00:35:57
